Eledon Pharmaceuticals announced the presentation of new long-term data from its Phase 2 BESTOW trial of tegoprubart for the prevention of rejection in kidney transplantation at the American Transplant Congress (ATC) held in 2026.
The data, presented on May 21, 2026, showed sustained efficacy and safety outcomes for tegoprubart, an anti-CD40L antibody, in kidney transplant recipients. The trial evaluated tegoprubart compared to standard of care in preventing organ rejection.
According to the company's press release, the long-term results demonstrated favorable graft survival and renal function, with no new safety signals identified. The findings support the potential of tegoprubart as a novel immunosuppressive therapy for transplant patients.
Eledon plans to advance tegoprubart into Phase 3 clinical trials based on these promising results. The full data set was presented at the ATC meeting in Boston, Massachusetts.
